Osmotica Pharmaceuticals PLC
F:O1P

Watchlist Manager
Osmotica Pharmaceuticals PLC Logo
Osmotica Pharmaceuticals PLC
F:O1P
Watchlist
Price: 0.003 EUR
Market Cap: 298k EUR

Operating Margin
Osmotica Pharmaceuticals PLC

-105.6%
Current
-23%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-105.6%
=
Operating Profit
-77.1m
/
Revenue
73.1m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Osmotica Pharmaceuticals PLC
F:O1P
298k EUR
-106%
US
Eli Lilly and Co
NYSE:LLY
997.2B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
503.6B USD
27%
CH
Roche Holding AG
SIX:ROG
252.5B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
211.1B GBP
24%
CH
Novartis AG
SIX:NOVN
205.8B CHF
33%
US
Merck & Co Inc
NYSE:MRK
244.4B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
145.2B USD
29%
No Stocks Found

Osmotica Pharmaceuticals PLC
Glance View

Market Cap
298k EUR
Industry
Pharmaceuticals

Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. The company is headquartered in Bridgewater, New Jersey and currently employs 302 full-time employees. The company went IPO on 2018-10-12. The firm is focused on the developing and commercialization of specialty products that target markets with underserved patient populations. The firm sells portfolio products consisting of promoted products and non-promoted products, which incorporate its Osmodex drug delivery system. The Company’s Osmodex drug delivery system uses osmotic pressure to provide a controlled drug release and is adaptable to many different combinations of immediate-release, extended-release and controlled- or delayed-release formulations that contain one or more drugs. The Company’s non-promoted product portfolio includes methylphenidate ER and venlafaxine extended-release tablets (VERT) as well as ANDAs and prescription dietary supplements. Its promoted products are led by Divigel and M-72 (methylphenidate hydrochloride extended-release tablets, 72 mg).

O1P Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-105.6%
=
Operating Profit
-77.1m
/
Revenue
73.1m
What is the Operating Margin of Osmotica Pharmaceuticals PLC?

Based on Osmotica Pharmaceuticals PLC's most recent financial statements, the company has Operating Margin of -105.6%.

Back to Top